Arcellx, Inc. Arcellx, Inc.

Arcellx, Inc.

ACLX

Classement en actions #2787
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Prix de l'action
$115.07
Dernière synchronisation: 2026-05-15
Capitalisation boursière
$6.73B
Changement (1 jour)
0.00%
Changement (1 an)
34.40%
Pays
US
Échange Arcellx, Inc. (ACLX)

Catégorie

Healthcare
Historique des divisions d’actions pour Arcellx, Inc. (ACLX)
L’action Arcellx, Inc. (symbole : ACLX) a subi un total de 0 divisions.
La division la plus récente a eu lieu le Oct 21, 2026.
Une action ACLX achetée avant le Oct 21, 2026 équivaudrait aujourd’hui à 0 actions ACLX.
Liste des divisions d’actions
Année Division Multiplicateur Multiplicateur cumulatif
Pas assez de données pour les dates fournies.
Divisions d’actions d’entreprises similaires ou concurrentes
Entreprise Nombre de divisions d’actions Multiplicateur cumulatif Pays
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL